Trials / Terminated
TerminatedNCT01349036
A Phase 2 Study of PLX3397 in Patients With Recurrent Glioblastoma
A Phase 2 Study of Orally Administered PLX3397 in Patients With Recurrent Glioblastoma
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 38 (actual)
- Sponsor
- Daiichi Sankyo · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to evaluate the response of subjects with recurrent glioblastoma to continuous therapy of PLX3397.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PLX3397 | Capsules administered once or twice daily, continuous dosing |
Timeline
- Start date
- 2011-12-03
- Primary completion
- 2013-11-05
- Completion
- 2013-11-05
- First posted
- 2011-05-06
- Last updated
- 2020-03-03
- Results posted
- 2020-01-09
Locations
6 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01349036. Inclusion in this directory is not an endorsement.